Business
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025
Late-breaking oral presentation details partial and complete proteinuria remission data from the DUPLEX Study of FILSPARI in FSGS Data presentations
About this update from Travere Therapeutics, Inc.
[{"type":"text","content":"\nLate-breaking oral presentation details partial and complete proteinuria remission data from the DUPLEX Study of FILSPARI in FSGS\n\nData presentations highlight SPARTAN Study results and real-world case studies of FILSPARI across different IgAN patient backgrounds\n\n SAN DIEGO--(BUSINESS WIRE)--\nTravere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present three abstracts, including one late-breaking oral presentation, at the upcoming National Kidney Foundation (NKF) Spring Clinical Meetings 2025, taking place April 10-13 in Boston, MA.\n\nThe late-breaking oral presentation will feature new analyses from the Phase 3 DUPLEX Study of FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS), showing that partial and complete proteinuria remission were achieved earlier and more frequently with FILSPARI than irbesartan, and patients that achieved proteinuria remission had low rates of kidney failure.\n\nThe Company will also present data that further explore the role of FILSPARI as a foundational therapy in IgA nephropathy (IgAN). Data from the Phase 2 SPARTAN Study of FILSPARI as first-line treatment in newly diagnosed patients with IgAN demonstrated rapid and sustained reductions in proteinuria, and reductions in sCD163 levels, an inflammatory biomarker associated with kidney injury. Additionally, a presentation of real-world case studies will show FILSPARI’s effectiveness across different IgAN patient backgrounds, including those with high proteinuria and prior treatments.\n\n“We look forward to presenting data exploring FILSPARI’s potential in FSGS where treatment options remain severely limited, as well as data that reinforce the medicine’s clinical benefits in IgAN,” said Jula Inrig, M.D., chief medical officer of Travere Therapeutics. “We remain committed to advancing research that supports improved outcomes for people living with rare kidney disease.”\n\nLate-Breaking Oral Presentation\n\nPatients in DUPLEX Achieved Partial or Complete Remission of Proteinuria Earlier and More Often with Sparsentan vs Irbesartan: Implications for Slowing Progression to Kidney Failure in FSGS\n\nPoster: LB-07\nSession: Late-Breaking Abstract Session\nDate: Thursday, April 10, 2025, 2:30-3:00 p.m. ET\nLocation: Convention Center Room 312\n\nPoster Presentations\n\nSparsentan as a First-Line Treatment ...